Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 143-155 , March 2006

Pediatric hemostasis and use of plasma components

  • Marilyn J. Manco-Johnson, MD (Director, Professor of Pediatrics)

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Mountain States Regional Hemophilia and Thrombosis Center, P.O. Box 6507, Mail Stop F-416, Aurora, CO 80045-0507, USA. Tel.: +1 303 724 0365; Fax: +1 303 724 0947.

References 

  1. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998–2005
  2. Flanders MM, Crist RA, Roberts WM, Rodgers GM. Pediatric reference intervals for ten coagulation assays. Blood. 2004;104:A2988;[Abstract]
  3. O'Shaughnessy DF, Atterbury C, Maggs PB, et al. (For the British Committee for Standards in Haematology Blood Transfusion Task Force.) Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28
  4. McAfee JH, Keeffe EB, Lee RG, Rosch J. Transjugular liver biopsy. Hepatology. 1992;15:726–732
  5. Denzer U, Helmreich-Becker I, Galle PR, Lohse AW. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol. 2003;98:893–900
  6. Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost. 2001;85:748–749
  7. Brown JB, Emerick KM, Brown DL, et al. Recombinant factor VIIa improved coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr. 2003;37:268–272
  8. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138–143
  9. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol. 1990;33:39–45
  10. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709
  11. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–592
  12. Churchwell KB, McManus ML, Kent P, et al. Intensive blood and plasma exchange for treatment of coagulopathy in meningococcemia. J Clin Apheresis. 1995;10:171–174
  13. Hellgren M, Javelin L, Hägnevik K, Blombäck M. Antithrombin III concentrate as adjuvant in DIC treatment: a pilot study in 9 severely ill patients. Thromb Res. 1984;35:459–466
  14. von Kries R, Stannigel H, Göbel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. Eur J Pediatr. 1985;144:191–194
  15. Hanada T, Abe T, Takita H. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children. Am J Pediatr Hematol Oncol. 1985;7:3–8
  16. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res. 1985;39:81–89
  17. Fuse S, Tomita H, Yoshida M, et al. High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children. Am J Hematol. 1996;53:18–21
  18. Eisele B, Lamy M, Keinecke HO, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 1998;24:663–672
  19. Kreuz WD, Schneider W, Nowak-Göttl U. Treatment of consumption cogulopathy with antithrombin concentrate in children with acquired antithrombin deficiency—a feasibility pilot study. Eur J Pediatr. 1999;158(supplement 3):S187–S191
  20. Dreyfus M, Magny JF, Briney F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med. 1991;325:1565–1568
  21. Gerson WT, Dickermann JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentate. Pediatrics. 1993;91:418–422
  22. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr. 1995;126:646–652
  23. Ettingshausen CE, Veldmann A, Beeg T, et al. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost. 1999;25:537–541
  24. Sajan I, Da-Silva SS, Dellinger RP. Drotrecogin alpha (activated) in an infant with Gram-negative septic shock. J Intensive Care Med. 2004;19:51–55
  25. Rock GA, Shumark KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–397
  26. Rock G, Shumark KH, Sutton DMC, et al. Cryosupernatant as replacement fluid for plasma exchange in the thrombotic thrombocytopenic purpura. Br J Haematol. 1996;39:1227–1234
  27. Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura. J Clin Apheresis. 2001;16:19–22
  28. Horton TM, Stone JD, Yee D, et al. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003;25:336–339
  29. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood. 2000;96:1223–1229
  30. Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolytic–uremic syndrome in children: results of a multicenter controlled trial. J Pediatr. 1988;112:284–290
  31. Loirat C, Sonsino E, Hinglais N, et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicenter randomized controlled trial. Pediatr Nephrol. 1988;2:279–285
  32. Gianviti A, Perna A, Caringella A, et al. Plasma exchange in children with hemolytic–uremic syndrome at risk of poor outcome. Am J Kidney Dis. 1993;22:264–266
  33. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. PNAS. 2003;100:12966–12971
  34. Yagi H, Konno M, Kinoshita S, et al. Plasma of patients with Upshaw–Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Haematol. 2001;115:991–997
  35. McDonald MM, Koops BL, Johnson ML, et al. Timing and antecedents of intracranial hemorrhage in the newborn. Pediatrics. 1984;74:32–36
  36. Beverley DW, Pitts-Tucker TJ, Congdon PJ, et al. Prevention of intraventricular haemorrhage by fresh frozen plasma. Arch Dis Child. 1985;60:710–713
  37. Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies: outcome at 2 years. Lancet. 1996;348:229–232
  38. Osborn DA, Evans N. Early volume expansion for prevention of morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. 2004;2:CD002055
  39. Mou SS, Giroir BP, Molitor-Kirsch EA, et al. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med. 2004;351:1635–1644
  40. Petaja J, Lundstrom U, Leijala M, et al. Bleeding and use of blood products after heart operations in infants. J Thorac Cardiovasc Surg. 1995;109:524–529
  41. Nicolas F, Daniel JP, Bruniaux J, et al. Conventional cardiopulmonary bypass in neonates. A physiological approach—10 years of experience at Marie–Lannelongue Hospital. Perfusion. 1994;9:41–48
  42. Chambers LA, Cohen DM, Davis JT. Transfusion patterns in pediatric open heart surgery. Transfusion. 1996;36:150–154
  43. Pychynska-Pokorska M, Moll JJ, Krajewski W, Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med. 2004;5:246–250
  44. Tobias JD, Simsic JM, Weinstein S, et al. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J Intensive Care Med. 2004;19:270–273
  45. Costello JM, Backer CL, de Hoyos A, et al. Aprotinin reduces operative closure time and blood product use after pediatric bypass. Ann Thorac Surg. 2003;75:1261–1266
  46. Reynolds LM, Nicholson SC, Jobes DR, et al. Desmopressin does not decrease bleeding after cardiac operation in your children. J Thorac Cardiovasc Surg. 1993;106:954–958
  47. Seear MD, Wadsworth LD, Rogers PC, et al. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg. 1989;98:217–219
  48. Rosenberg EM, Chambers LA, Gunter JM, Good JA. A program to limit donor exposures to neonates undergoing extracorporeal membrane oxygenation. Pediatrics. 1994;94:341–346
  49. McCoy-Pardington D, Judd WJ, Knafl P, et al. Blood use during extracorporeal membrane oxygenation. Transfusion. 1990;30:307–309
  50. Supapannachart S, Siripoonya P, Boonwattanasoontorn W, Kanjanavanit A. Neonatal polycythemia: effects of partial exchange transfusion using fresh frozen plasma, haemaccel and normal saline. J Med Assoc Thai. 1999;82(supplment 1):S82–S86
  51. Deorari AK, Paul VK, Shreshta L, Singh M. Symptomatic neonatal polycythemia: comparison of partial exchange transfusion with saline versus plasma. Indian Pediatr. 1995;32:1167–1171
  52. Roithmaier A, Arlettaz R, Bauer K, et al. Randomized controlled trial of Ringer solution versus serum for partial exchange transfusion in neonatal polycythaemia. Eur J Pediatr. 1995;154:53–56
  53. Tothenberg T. Partial plasma exchange transfusion in polycythemic neonates. Arch Dis Child. 2002;86:60–62
  54. Rosenkrantz TS. Polycythemia and hyperviscosity in the newborn. Semin Thromb Hemost. 2003;29:515–527
  55. McLeod BC, Sassetti RJ, Cole ER, Scott JP. Long-term frequent plasma exchange donation of cryoprecipitate. Transfusion. 1988;28:307–310
  56. McLeod BC, Scott JP. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII. Prog Clin Biol Res. 1990;324:189–198
  57. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997;90:204–208
  58. Brummel Ziedins K, Rivard GE, Pouliot RL, et al. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost. 2004;2:1735–1744

PII: S1521-6926(05)00073-3

doi: 10.1016/j.beha.2005.03.006

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 143-155 , March 2006

Article Tools